ÄÁº¥¼Ç AȦ |
ÄÁº¥¼Ç BȦ |
08:30-09:00 |
µî·Ï |
09:00-09:10 |
Àλ縻 |
ÀüÈÆÀç ÀÌ»çÀå´Ô |
09:10-10:20 |
Session I. ASCO/ESMO GI Cancer Symposium 2020 review (What is the NEW?) |
ÁÂÀå: Á¤Çö¿ë/¹æ½Â¹Î |
09:10-10:20 |
Plenary session (Free paper presentation) |
ÁÂÀå: ¹Ú¼±ÀÚ/¹ÚÁ¤¿± |
09:10-09:30 |
1. Upper GI tract |
°¼±Çü(Ãæ³²´ë) |
09:10-09:20 |
1. Anastomotic leakage and chronic presacral sinus after transanal total mesorectal excision (taTME) for rectal cancer: Comparative study to laparoscopic TME |
¹®¼º¹Ì(°¡Å縯´ë) |
09:20-09:30 |
2. A simple scoring model using endoscopic features for selection of colorectal cancer amenable to endoscopic resection |
À¯Á¾¿í(¿¬¼¼´ë) |
09:30-09:50 |
2. Lower GI tract |
±ÃÇöÁ¤(¼øõÇâ´ë) |
09:30-09:40 |
3. Comparison of the microbiome diversity in gastric cancer patients and in Non-cancerous patients |
¹æÀºÁÖ(°í·Á´ë) |
09:40-09:50 |
4. Serial ctDNA monitoring in metastatic pancreatic cancer: A prospective clinical validation study |
Á¤±¤·Ï(¼¿ï´ë) |
09:50-10:10 |
3. Pancreatobiliary tract |
ÀüÁß¿ø(±¹¸³¾Ï¼¾ÅÍ) |
09:50-10:00 |
5. Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients |
ÇѼº¿ë(ºÎ»ê´ë) |
10:00-10:10 |
6. Programmed death-ligand 1 expression on tumor infiltrating immune cells is associated with better prognosis in biliary |
±Ç¼ºÂù(¿¬¼¼´ë) |
10:10-10:20 |
Q&A |
10:10-10:20 |
7. Optimal adjuvant therapy in patients with borderline resectable and unresectable pancreatic cancer who had received neoadjuvant FOLFIRINOX |
ÃÖÁøÈ£(¼¿ï´ë) |
10:20-10:40 |
Coffee break |
10:40-12:20 |
Session II. IASGO joint session : debate for challenging situations in GI malignancy |
ÁÂÀå: ÀüÈÆÀç/¹Ú¹«ÀÎ |
Session II. IASGO joint session: debate or controversial issues of PB malignancy |
ÁÂÀå: ¼Û½Ã¿µ/¿ì»ó¸í |
10:40-11:00 |
1. Surgical roles for GE junction cancer: MIS with radicality and multimodality |
Ming Tsan Lin (National Taiwan University Hospital) |
1. Neoadjuvant therapy in resectable and borderline resectable |
Á¶Àη¡(¼¿ï´ë) |
11:00-11:20 |
2. Periperatative chemotherapy for locally advaced GE junction cancer |
±èÅÂÈ£(°¡Å縯´ë) |
2. Upfront surgery in resectable (R) pancreatic cancer (PC), focusing on clinical benefits of neoadjuvant chemoradiotherapy versus up-front surgery for PC patients |
Shugo Mizuno (Mie University) |
11:20-11:40 |
3. Radical surgery for rectal cancer after complete remission induced by CRT |
Soichiro Ishihara (The University of Tokyo Graduate School of Medicine) |
3. Neoadjuvant chemotherapy vs. chemoradiotherapy in locally advanced pancreatic cancer: FOLFIRINOX |
Á¤¹®Àç(¿¬¼¼´ë) |
11:40-12:00 |
4. Local excision or watch and wait for rectal cancer after CRT (or neoadjuvant therapy) with complete remission |
±è¹ÎÁ¤ (¼¿ï´ë) |
4. Roles of conversion surgery for unresectable metastatic pancreatic cancer |
Masayuki Sho (Nara Medical University) |
12:20-13:30 |
Luncheon symposium |
ÁÂÀå: ÀüÈÆÀç |
12:20-13:00 |
The role of gemcitabine in pancreatie cancer |
¹æ½Â¹Î(¿¬¼¼´ë) |
13:00-13:30 |
ÃÑȸ |
13:30-15:00 |
Session III. From bench to clinic, emerging issues on gastrointestinal cancer |
ÁÂÀå: ÃÖÈ£¼ø/ÁøÀ±Å |
13:30-15:00 |
Session III. Appilcation of AI and big data in gastrointestinal cancers |
ÁÂÀå : ·ùÁö°ï/ÀÓÀ±Á¤ |
13:30-13:50 |
1. Present and future of Microbiome in GI cancers |
¹ÚÇѼö(±¤ÁÖ°ú±â¿ø) |
13:30-13:50 |
1. Big data analysis with the national health information database |
±è¼ö¿µ(¿¬¼¼´ë ¿øÁÖ) |
13:50-14:10 |
2. Application of the organoid in GI cancers |
±¸ÀÚ·Ï(¼¿ï´ë) |
13:50-14:10 |
2. Cancer research using National Health Insurance big data |
¹Úº´±Ô(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø) |
14:10-14:30 |
3. Circulating tumor DNA as Biomarkers in GI cancer |
±èµ¿¿í(ºÎ»ê´ë) |
14:10-14:30 |
3. Image analysis with artificial intelligence in gastric cancer |
¹æâ¼®(ÇѸ²´ë) |
14:30-14:50 |
4. Single-cell analysis: New armamentarium for translational GI cancer research |
ÀÌÇý¿Á(Ä«Å縯´ë) |
14:30-14:50 |
4. How to approach artificial intelligence: Guided by AI expert |
±è±¤±â(°¡Ãµ´ë) |
14:50-15:00 |
Q&A |
14:50-15:00 |
Q&A |
15:00-15:20 |
Coffee break |
15:20-17:10 |
Session IV. Immunotherapy and target therapy of gastrointestinal cancers |
ÁÂÀå: ±èÈ£°¢/ȲÁøÇõ |
15:20-17:10 16:00-16:50 |
Free paper session I Free paper session II |
ÁÂÀå:±èÇö¼ö/ÀÌ»óÇù ÁÂÀå:±èº´Ã¢/ÇÑÁ¤È£ |
15:20-15:40 |
1. Introduction of immunotherapy and experience in other malignancy |
±¸µ¿È¸(¼º±Õ°ü´ë) |
15:20-15:28 |
S-1. Impact of gross tumor morphology on the clinical outcomes of Non-metastatic colon cancer: Multicenter retrospective cohort study |
ÇѼÒÁ¤(¿¬¼¼´ë) |
15:28-15:36 |
S-2. BRCA 1/2 mutation predicts the treatment response of FOLFIRINOX in patients with pancreatic ductal adenocarcinoma |
¹ÚÁöÈÆ(¿¬¼¼´ë) |
15:36-15:44 |
S-3. Prognostic significance of lymph node status in resected ampullary adenocarcinoma followed by adjuvant chemotherapy |
¹Ú³²¿µ(¼¿ï´ë) |
15:40-16:00 |
2. Prospects for immunotherapy and targeted therapy in gastric cancer |
¹®Èñ¼®(Ãæ³²´ë) |
15:44-15:52 |
S-4. M-RNA expression of signet ring cell carcinoma is different from that of poorly cohesive carcinoma in early gastric cancer |
°¼±Çü(Ãæ³²´ë) |
15:52-16:00 |
S-5. Serum biomarker panels for the detection of pancreatic cancer |
½Åµ¿¿ì(¼¿ï´ë) |
16:00-16:20 |
3. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy |
±èÀº¼±(°í·Á´ë) |
16:00-16:08 |
S-6. Development of a cachexia-diagnostic model using trajectories of skeletal muscle change |
±è½Ã¿µ(¿¬¼¼´ë) |
16:08-16:16 |
S-7. Predicting pulmonary thromboembolism in patients with gastrointestinal cancer using XGBoost machine learning model |
±èÁÖ¼º(¼¿ï´ë) |
16:16-16:24 |
S-8. A new approaching technique of fluoroscopic-guided biliary biopsy for bile duct stenosis with loop tip guidewire |
ÀÌ°¿ø(°í·Á´ë) |
16:20-16:40 |
4. Promising immunotherapy and targeted therapy in pancreatobilary cancer |
¹ÚÁÖ°æ(¼º±Õ°ü´ë) |
16:24-16:32 |
S-9. Effect of fruit and vegetable intake on the risk of esophageal cancer in a large cohort |
¹ÚÁ¤È£(°æºÏ´ë) |
16:32-16:40 |
S-10. Long term safety and efficacy of etomidate in comparison with propofol as sedative in gastric neoplasm for endoscopic submucosal dissection |
ÀüÇÑÁ¶(°í·Á´ë) |
16:40-16:50 |
Q&A |
16:40-16:50 |
Q&A |
16:50-17:10 |
Best presentation award |
17:10- |
Adjourn |